

**INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT
 BENZODIAZEPINE AND OPIOID CONCURRENT THERAPY
 PRIOR AUTHORIZATION REQUEST FORM**



MDwise
 Fax to: (858) 790-7100
 c/o MedImpact Healthcare Systems, Inc.
 Attn: Prior Authorization Department
 10181 Scripps Gateway Court, San Diego, CA 92131
 Phone: 1-800-788-2949



Today's Date

/ /

Note: This form must be completed by the prescribing provider.

****All sections must be completed or the request will be denied.****

Patient's Medicaid #	<input type="text"/>	Date of Birth	<input type="text"/> / <input type="text"/> / <input type="text"/>
Patient's Name	Prescriber's Name		
Prescriber's IN License #	<input type="text"/>	Specialty	
Prescriber's NPI #	<input type="text"/>	Prescriber's Signature: **Required below within attestation section.**	
Return Fax #	<input type="text"/> - <input type="text"/> - <input type="text"/>	Return Phone #	<input type="text"/> - <input type="text"/> - <input type="text"/>

PA is required for the following:

- Claim(s) for new opioid(s) to be used concurrently with benzodiazepines and exceeding 7 days within a 180-day period.
- Claim(s) for new benzodiazepine(s) to be used concurrently with opioids and exceeding 7 days of therapy within a 180-day period and/or exceeding established benzodiazepine/opioid concurrent therapy quantity limits (see Sedative Hypnotics/Benzodiazepine PA criteria).

Requested Benzodiazepine(s)	Prescriber Name*	Quantity	Dosage Regimen/Duration

Requested Opioid(s)	Prescriber Name*	Quantity	Dosage Regimen/Duration

***NOTE: If prescribers of the opioid(s) and benzodiazepine(s) are not the same, please answer the following questions:**

- Is/are the other prescriber(s) aware of the request for concurrent therapy? Yes No
- Has/have the other prescriber(s) been consulted about the risks associated with concurrent therapy, and do all prescribers involved believe continuing with concurrent therapy is warranted, given the risks associated with concurrent use? Yes No

PA Requirements:

Patient diagnosis/diagnoses for use of benzodiazepine therapy:

Prior therapies attempted for the above diagnosis/diagnoses:

Drug Therapy	Dosage Regimen	Dates of Utilization

Do you plan to continue benzodiazepine therapy for this patient? Yes No
If no, please provide withdrawal plan:

Patient diagnosis/diagnoses for use of opioid therapy:

Prior therapies (both drug and non-drug) attempted for the above diagnosis/diagnoses:

Drug/Non-Drug Therapy	Dosage Regimen	Dates of Utilization	Reason for Discontinuation or Failure

Do you plan to continue opioid therapy for this patient? Yes No
If no, please provide withdrawal plan:

Attestation:

I, _____, hereby attest to the following:
(Prescriber Name)

- The patient's INSPECT report has been evaluated and continues to be evaluated on a regular basis (Per IC 35-48-7-11.1, DO NOT attach a copy of the INSPECT report to this PA request).
- I have educated the patient in regards to the risks of concurrent utilization of benzodiazepine and opioid therapy, and the patient accepts these risks.
- If applicable, I have consulted other prescriber(s) involved in concurrent therapy and all prescribers involved agree to pursue concurrent opioid and benzodiazepine therapy for this patient.
- I acknowledge, as the prescriber initiating or maintaining concurrent benzodiazepine and opioid therapy, the risk of adverse event(s), including respiratory depression, coma, and death, associated with concurrent utilization.

Prescriber Signature: _____

****Prescriber signature is required for consideration. Electronic or stamped signature will not be accepted.****

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.